Investigation summary: samples unavailable, complaint was not raised on a specific lot number of posiflush sf or sp.Complaint raised in association with an fda investigation of infections in patients with central lines whose treatment involved the use of posiflush sp, sf, and heparin lock syringes.Lot number unknown.Dhr - n/a - lot number unknown.- the provided lot numbers for this complaint were reviewed and concluded not to be manufactured in drogheda.Manufacturing review: the organism associated with the complaint was identified as serratia marcescens.A review of environmental monitoring data from 2015-2018 and bioburden ids confirmed that the organism has never been recorded at the drogheda site.Unconfirmed.Investigation comments- n/a (no sample or lot).Other action taken: there is no morphological evidence of serratia marcescens ability to survive the moist heat sterilization process.During the validation and annual re-validation of the drogheda steam sterilizers, the plant uses spore forming thermophilic gram positive rod shaped geobacillus stearmothermophillus s a biological indicator.The formation of endospores has not been reported in any species of serratia, thus its resistance to steam sterilization is scientifically remote.In addition, it is a mobile organism with growing conditions of 5-40 degrees celsius, well below the moist heat sterilization temperature of 121 degrees celsius.Investigation conclusion: root cause: a batch number was not supplied in this instance.However, in accordance with (b)(4), situational analysis, a three year review of complaints, environmental monitoring results, water test results and quality notifications was performed.Records indicate that there were no recorded occurrences of s.Marcescens organism in the drogheda plant.In addition, drogheda posiflush product is terminally sterilized with moist heat sterilization.The sterilization process is requalified annually to demonstrate sterility assurance level of >10-6.
|